

April 21, 2020

Stayble publishes the Annual Report for 2019

Gothenburg, April 21, 2020 – Stayble Therapeutics, today announced the publication of the Annual Report 2019.

The Annual Report is available on the company's website:

<http://staybletherapeutics.com/investor-relations/financial-reports/>

For more information

Andreas Gerward, CEO Stayble Therapeutics AB

andreas.gerward@stayble.se

+46 730 808 397

About Stayble Therapeutics AB

Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient's life and to require minimal rehabilitation. The Company's focus is set upon the continued clinical development of the upcoming clinical phase 2b study. Stayble's vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.

Mangold Fondkommission AB is the Company's Certified Adviser and can be reached at +46 (0)8 503 015 50 or e-mail ca@mangold.se.